A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2

被引:0
|
作者
Chatterton, Carolyn [1 ,2 ,3 ]
Romero, Roberto [1 ,2 ,4 ,5 ,6 ,7 ]
Jung, Eunjung [1 ,2 ,3 ]
Gallo, Dahiana M. [1 ,2 ,3 ,8 ]
Suksai, Manaphat [1 ,2 ,3 ]
Diaz-Primera, Ramiro. [1 ,2 ,6 ]
Erez, Offer [1 ,2 ,3 ,9 ]
Chaemsaithong, Piya [1 ,2 ,3 ,10 ]
Tarca, Adi L. [1 ,2 ,3 ,11 ]
Gotsch, Francesca [1 ,2 ,3 ]
Bosco, Mariachiara [1 ,2 ,3 ]
Chaiworapongsa, Tinnakorn [1 ,2 ,3 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child, Pregnancy Res Branch, Div Obstet & Maternal Fetal Med, Div Intramural Res,NIH,USDHHS,NICHD,DHHS, Bethesda, MD 20892 USA
[2] Eunice Kennedy Shriver Natl Inst Child, Pregnancy Res Branch, Div Obstet & Maternal Fetal Med, Div Intramural Res,NIH,USDHHS,NICHD,DHHS, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA
[4] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA
[5] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA
[6] Wayne State Univ, Ctr Mol Med & Genet, Detroit, MI 48201 USA
[7] Detroit Med Ctr, Detroit, MI 48201 USA
[8] Univ Valle, Dept Gynecol & Obstet, Cali, Colombia
[9] Soroka Univ Med Ctr, Dept Obstet & Gynecol, Beer Sheva, Israel
[10] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Maternal Fetal Med, Bangkok, Thailand
[11] Wayne State Univ Engn, Dept Comp Sci, Detroit, MI USA
来源
基金
美国国家卫生研究院;
关键词
Cytokines; IL-1; IL-33; pregnancy; sepsis; septic shock; urinary tract infection; HUMAN ST2 GENE; BLOOD CULTURES; SEPTIC SHOCK; INFLAMMATORY RESPONSE; ANTIBIOTIC-TREATMENT; ANGIOGENIC FACTORS; DIAGNOSTIC MARKER; IMMUNE-RESPONSE; MATERNAL DEATHS; PROMOTER USAGE;
D O I
10.1080/14767058.2023.2183470
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Sepsis is a leading cause of maternal death, and its diagnosis during the golden hour is critical to improve survival. Acute pyelonephritis in pregnancy is a risk factor for obstetrical and medical complications, and it is a major cause of sepsis, as bacteremia complicates 15-20% of pyelonephritis episodes in pregnancy. The diagnosis of bacteremia currently relies on blood cultures, whereas a rapid test could allow timely management and improved outcomes. Soluble suppression of tumorigenicity 2 (sST2) was previously proposed as a biomarker for sepsis in non-pregnant adults and children. This study was designed to determine whether maternal plasma concentrations of sST2 in pregnant patients with pyelonephritis can help to identify those at risk for bacteremia. Study design: This cross-sectional study included women with normal pregnancy (n = 131) and pregnant women with acute pyelonephritis (n = 36). Acute pyelonephritis was diagnosed based on a combination of clinical findings and a positive urine culture. Patients were further classified according to the results of blood cultures into those with and without bacteremia. Plasma concentrations of sST2 were determined by a sensitive immunoassay. Non-parametric statistics were used for analysis. Results: The maternal plasma sST2 concentration increased with gestational age in normal pregnancies. Pregnant patients with acute pyelonephritis had a higher median (interquartile range) plasma sST2 concentration than those with a normal pregnancy [85 (47-239) ng/mL vs. 31 (14-52) ng/mL, p < .001]. Among patients with pyelonephritis, those with a positive blood culture had a median plasma concentration of sST2 higher than that of patients with a negative blood culture [258 (IQR: 75-305) ng/mL vs. 83 (IQR: 46-153) ng/mL; p = .03]. An elevated plasma concentration of sST2 >= 215 ng/mL had a sensitivity of 73% and a specificity of 95% (area under the receiver operating characteristic curve, 0.74; p = .003) with a positive likelihood ratio of 13.8 and a negative likelihood ratio of 0.3 for the identification of patients who had a positive blood culture. Conclusion: sST2 is a candidate biomarker to identify bacteremia in pregnant women with pyelonephritis. Rapid identification of these patients may optimize patient care.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells
    Delesque, N
    Buscail, L
    Esteve, JP
    SaintLaurent, N
    Muller, C
    Weckbecker, G
    Bruns, C
    Vaysse, N
    Susini, C
    CANCER RESEARCH, 1997, 57 (05) : 956 - 962
  • [32] Relation between soluble suppression of tumorigenicity 2 (sST2) and brain natriuretic peptide (BNP) in healthy pediatric subjects: from birth through adulthood
    Caselli, C.
    Ragusa, R. R.
    Cantinotti, C. M.
    D'Amico, D. A. A.
    Storti, S. S.
    Cabiati, C. M.
    Clerico, A.
    Federico, G.
    Trivella, M. G.
    Del Ry, S.
    EUROPEAN HEART JOURNAL, 2015, 36 : 797 - 797
  • [33] TAVI leads to a peri-procedural increase of biomarker sST2 through hemodynamic stress but failed to alter sST2 concentration in the long term
    Wernly, B.
    Lichtenauer, M.
    Eder, S.
    Edlinger, C.
    Landmesser, U.
    Figulla, H.
    Hoppe, U.
    Jung, C.
    Lauten, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S286 - S287
  • [34] Soluble ST2 (sST2) as potential marker for hepatic cystic echinococcosis activity
    An, Mengting
    Zhu, Yuejie
    Xu, Cheng
    Li, Yujiao
    Pang, Nannan
    Zhao, Xiao
    Li, Zhiwei
    Wang, Hongying
    Zhang, Fengbo
    Ding, Jianbing
    JOURNAL OF INFECTION, 2020, 80 (04) : 462 - 468
  • [35] The biomarker sst2 is an independent predictor for acute kidney injury in patients with st segment elevation myocardial infarction
    Vyshnevska, I. R.
    Hilova, Y. V.
    Petyunina, O. V.
    Kopytsya, M. P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 615 - 615
  • [36] The sst2 somatostatin receptor subtype is a tumor suppressor gene for human pancreatic cancer
    Delesque, N
    Buscail, L
    Esteve, JP
    SaintLaurent, N
    Muller, C
    Capella, G
    Weckbecker, G
    Bruns, C
    Vaysse, N
    Susini, C
    GASTROENTEROLOGY, 1996, 110 (04) : A507 - A507
  • [37] Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T
    Dispenzieri, Angela
    Gertz, Morie A.
    Saenger, Amy
    Kumar, Shaji K.
    Lacy, Martha Q.
    Buadi, Francis K.
    Dingli, David
    Leung, Nelson
    Zeldenrust, Steven
    Hayman, Suzanne R.
    Kapoor, Prashant
    Grogan, Martha
    Hwa, Lisa
    Russell, Stephen J.
    Go, Ronald S.
    Rajkumar, S. Vincent
    Kyle, Robert A.
    Jaffe, Allan
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 524 - 528
  • [38] SOLUBLE SUPPRESSION OF TUMORIGENICITY 2 (SST2) AND CARDIOVASCULAR OUTCOMES IN PERSONS WITH TYPE 2 DIABETES MELLITUS RANDOMIZED TO DAPAGLIFLOZIN OR PLACEBO: ANALYSES FROM THE DECLARE-TIMI 58 TRIAL
    Haller, Paul
    Wiviott, Stephen
    Jarolim, Petr
    Goodrich, Erica L.
    Bhatt, Deepak L.
    Gause-Nilsson, Ingrid
    Leiter, Lawrence A.
    McGuire, Darren K.
    Raz, Itamar
    Wilding, John
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 378 - 378
  • [39] Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
    Magro, F.
    Lopes, S.
    Silva, M.
    Coelho, R.
    Portela, F.
    Branquinho, D.
    Correia, L.
    Fernandes, S.
    Cravo, M.
    Caldeira, P.
    Sousa, H.
    Patita, M.
    Lago, P.
    Ramos, J.
    Afonso, J.
    Redondo, I.
    Machado, P.
    Philip, G.
    Lopes, J.
    Carneiro, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S363 - S363
  • [40] Plasma Soluble ST2 (sST2) levels are Higher in Neurodegeneration and Associate with PD Cognition
    Ng, A.
    Tan, Y. J.
    Yong, A.
    Wong, B.
    Lu, Z. H.
    Ng, S.
    Ting, S.
    Hameed, S.
    Zeng, L.
    Kandiah, N.
    Au, W. L.
    Tan, L.
    MOVEMENT DISORDERS, 2019, 34 : S700 - S701